Literature DB >> 16760800

Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe.

Wendy P Bannister1, Ole Kirk, Jose M Gatell, Brygida Knysz, Jean-Paul Viard, Helene Mens, Antonella D'Arminio Monforte, Andrew N Phillips, Amanda Mocroft, Jens D Lundgren.   

Abstract

BACKGROUND: Changes in virologic response to initial combination antiretroviral therapy (cART) over calendar time may indicate improvements in cART or emergence of primary resistance. Regional variations may identify differences in available antiretroviral drugs or patient management.
METHODS: Virologic response (viral load < 500 copies/mL) 6 to 12 months after starting cART was analyzed in antiretroviral-naive EuroSIDA patients. Analyses were stratified by region (south, central west, north, east) or time started cART (early, 1996-1997; mid, 1998-1999; late, 2000-1904).
RESULTS: Virologic suppression was achieved by 60% of 2102 patients: 57% south (n = 560), 61% central west (n = 466), 63% north (n = 606), 58% east (n = 470) (P = 0.091). An increase was observed over time: 52% early cART, 56% mid cART, 69% late cART (P < 0.001). Overall, there were significant effects of region (P = 0.026) and time (P < 0.001) on virologic response after adjustment for confounders. Stratified by period, regional differences were less evident (early cART, P = 0.967; mid cART, P = 0.291; late cART, P = 0.163). Stratified by region, temporal changes were observed (south, P = 0.061; central west, P < 0.001; north: P = 0.070; east, P = 0.001).
CONCLUSIONS: There was some evidence of regional differences in initial virologic response to cART. Improvements over time were observed, suggesting that so far, the effect of primary resistance has not been of sufficient magnitude to prevent increasing suppression rates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760800     DOI: 10.1097/01.qai.0000214815.95786.31

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

Review 1.  When should antiretroviral therapy for HIV be started?

Authors:  Andrew N Phillips; Brian G Gazzard; Nathan Clumeck; Marcelo H Losso; Jens D Lundgren
Journal:  BMJ       Date:  2007-01-13

Review 2.  Antiretroviral therapy : optimal sequencing of therapy to avoid resistance.

Authors:  Jorge L Martinez-Cajas; Mark A Wainberg
Journal:  Drugs       Date:  2008       Impact factor: 9.546

3.  Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america.

Authors:  Alison G Abraham; Bryan Lau; Steven Deeks; Richard D Moore; Jinbing Zhang; Joseph Eron; Richard Harrigan; M John Gill; Mari Kitahata; Marina Klein; Sonia Napravnik; Anita Rachlis; Benigno Rodriguez; Sean Rourke; Constance Benson; Ron Bosch; Ann Collier; Kelly Gebo; James Goedert; Robert Hogg; Michael Horberg; Lisa Jacobson; Amy Justice; Greg Kirk; Jeff Martin; Rosemary McKaig; Michael Silverberg; Timothy Sterling; Jennifer Thorne; James Willig; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2011-08-03       Impact factor: 4.897

Review 4.  The role of HIV in serious diseases other than AIDS.

Authors:  Andrew N Phillips; James Neaton; Jens D Lundgren
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

5.  Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.

Authors:  David Charles Boettiger; Stephen Kerr; Rossana Ditangco; Tuti Parwati Merati; Thuy Thi Thanh Pham; Romanee Chaiwarith; Sasisopin Kiertiburanakul; Chung Ki Patrick Li; Nagalingeswaran Kumarasamy; Saphonn Vonthanak; Christopher Lee; Nguyen Van Kinh; Sanjay Pujari; Wing Wai Wong; Adeeba Kamarulzaman; Fujie Zhang; Evy Yunihastuti; Jun Yong Choi; Shinichi Oka; Oon Tek Ng; Pacharee Kantipong; Mahiran Mustafa; Winai Ratanasuwan; Annette Sohn; Matthew Law
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

6.  A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.

Authors:  A Mocroft; P Reiss; A Rakhmanova; D Banhegyi; A N Phillips; S De Wit; M Ristola; J D Lundgren; J Grarup; O Kirk
Journal:  Infection       Date:  2014-06-06       Impact factor: 3.553

7.  Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study).

Authors:  Ann K Sullivan; Dorthe Raben; Joanne Reekie; Michael Rayment; Amanda Mocroft; Stefan Esser; Agathe Leon; Josip Begovac; Kees Brinkman; Robert Zangerle; Anna Grzeszczuk; Anna Vassilenko; Vesna Hadziosmanovic; Maksym Krasnov; Anders Sönnerborg; Nathan Clumeck; José Gatell; Brian Gazzard; Antonella d'Arminio Monforte; Jürgen Rockstroh; Jens D Lundgren
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

8.  The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

Authors:  Jurgen Vercauteren; Koen Deforche; Kristof Theys; Michiel Debruyne; Luis Miguel Duque; Susana Peres; Ana Patricia Carvalho; Kamal Mansinho; Anne-Mieke Vandamme; Ricardo Camacho
Journal:  Retrovirology       Date:  2008-02-01       Impact factor: 4.602

9.  Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

Authors:  D Raben; A Mocroft; M Rayment; V M Mitsura; V Hadziosmanovic; Z M Sthoeger; A Palfreeman; S Morris; G Kutsyna; A Vassilenko; J Minton; C Necsoi; V P Estrada; A Grzeszczuk; V Svedhem Johansson; J Begovac; E L C Ong; A Cabié; F Ajana; B M Celesia; F Maltez; M Kitchen; L Comi; U B Dragsted; N Clumeck; J Gatell; B Gazzard; A d'Arminio Monforte; J Rockstroh; Y Yazdanpanah; K Champenois; M L Jakobsen; A Sullivan; J D Lundgren
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

10.  Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in Uganda.

Authors:  Barbara Castelnuovo; Agnes Kiragga; Joseph Musaazi; Joseph Sempa; Frank Mubiru; Jane Wanyama; Bonnie Wandera; Moses Robert Kamya; Andrew Kambugu
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.